TP53 and colorectal carcinoma: Studies with the eight-item CWS and using the suggested cut-off (≥14 total score) [9] have identified high cancer worry in 31% of breast cancer survivors [9], 38% of CRC survivors [21], 33% of pancreatic ductal adenocarcinoma surveillance participants [16], and 47% of TP53-mutation carriers [34].